EA202090119A1 - Аморфные и кристаллические формы ido-ингибиторов - Google Patents
Аморфные и кристаллические формы ido-ингибиторовInfo
- Publication number
- EA202090119A1 EA202090119A1 EA202090119A EA202090119A EA202090119A1 EA 202090119 A1 EA202090119 A1 EA 202090119A1 EA 202090119 A EA202090119 A EA 202090119A EA 202090119 A EA202090119 A EA 202090119A EA 202090119 A1 EA202090119 A1 EA 202090119A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- crystalline forms
- amorphic
- ido inhibitors
- methods
- ido
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- KRTIYQIPSAGSBP-KLAILNCOSA-N linrodostat Chemical compound C1(CCC(CC1)C1=C2C=C(F)C=CC2=NC=C1)[C@@H](C)C(=O)NC1=CC=C(Cl)C=C1 KRTIYQIPSAGSBP-KLAILNCOSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527855P | 2017-06-30 | 2017-06-30 | |
| PCT/US2018/040262 WO2019006283A1 (en) | 2017-06-30 | 2018-06-29 | AMORPHOUS AND CRYSTALLINE FORMS OF IDO INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202090119A1 true EA202090119A1 (ru) | 2020-04-21 |
Family
ID=64742242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202090119A EA202090119A1 (ru) | 2017-06-30 | 2018-06-29 | Аморфные и кристаллические формы ido-ингибиторов |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11236049B2 (https=) |
| EP (1) | EP3644993B1 (https=) |
| JP (1) | JP7690284B2 (https=) |
| KR (1) | KR102630575B1 (https=) |
| CN (1) | CN111093651B (https=) |
| AU (1) | AU2018294314B2 (https=) |
| CA (1) | CA3066789A1 (https=) |
| EA (1) | EA202090119A1 (https=) |
| IL (1) | IL271601B2 (https=) |
| MX (2) | MX391848B (https=) |
| SG (1) | SG11201911937UA (https=) |
| WO (1) | WO2019006283A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7315483B2 (ja) * | 2017-06-30 | 2023-07-26 | ブリストル－マイヤーズ スクイブ カンパニー | 置換キノリニルシクロヘキシルプロパンアミド化合物および改良されたその製造方法 |
| EP4426022A3 (en) * | 2017-11-17 | 2024-11-20 | Telefonaktiebolaget LM Ericsson (publ) | Signaling ta-offset in nr |
| CN110357813A (zh) * | 2018-04-09 | 2019-10-22 | 信达生物制药(苏州)有限公司 | 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途 |
| WO2020000236A1 (zh) * | 2018-06-27 | 2020-01-02 | 深圳仁泰医药科技有限公司 | (r)-n-(4-氯苯基)-2-(顺-4-(6-氟喹啉-4-基)环己基)丙酰胺的晶型 |
| WO2021050653A1 (en) * | 2019-09-11 | 2021-03-18 | Bristol-Myers Squibb Company | Pharmaceutical formulations of indoleamine 2, 3-dioxygenase inhibitors |
| BR112022009944A2 (pt) * | 2019-11-26 | 2022-08-09 | Bristol Myers Squibb Co | Sais / cocristais de (r)-n-(4-clorofenil)-2-((1s,4s)-4-(6-fluoroquinolin-4-il)ciclo-hexil)propanamida |
| AR120935A1 (es) * | 2020-01-02 | 2022-03-30 | Hutchison Medipharma Ltd | Derivados de amida y usos de los mismos |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| WO2009156652A1 (fr) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Structure en nid d'abeille a base de titanate d'aluminium |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| UY36390A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| UY36391A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| JP7315483B2 (ja) | 2017-06-30 | 2023-07-26 | ブリストル－マイヤーズ スクイブ カンパニー | 置換キノリニルシクロヘキシルプロパンアミド化合物および改良されたその製造方法 |
-
2018
- 2018-06-29 EP EP18823337.3A patent/EP3644993B1/en active Active
- 2018-06-29 WO PCT/US2018/040262 patent/WO2019006283A1/en not_active Ceased
- 2018-06-29 EA EA202090119A patent/EA202090119A1/ru unknown
- 2018-06-29 KR KR1020207002491A patent/KR102630575B1/ko active Active
- 2018-06-29 CA CA3066789A patent/CA3066789A1/en active Pending
- 2018-06-29 CN CN201880044036.6A patent/CN111093651B/zh active Active
- 2018-06-29 SG SG11201911937UA patent/SG11201911937UA/en unknown
- 2018-06-29 IL IL271601A patent/IL271601B2/en unknown
- 2018-06-29 AU AU2018294314A patent/AU2018294314B2/en active Active
- 2018-06-29 JP JP2020500206A patent/JP7690284B2/ja active Active
- 2018-06-29 US US16/624,490 patent/US11236049B2/en active Active
- 2018-06-29 MX MX2019014885A patent/MX391848B/es unknown
-
2019
- 2019-12-10 MX MX2021015656A patent/MX2021015656A/es unknown
-
2021
- 2021-12-16 US US17/553,434 patent/US12421195B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3066789A1 (en) | 2019-01-03 |
| IL271601B1 (en) | 2024-01-01 |
| IL271601B2 (en) | 2024-05-01 |
| CN111093651A (zh) | 2020-05-01 |
| US20200115342A1 (en) | 2020-04-16 |
| WO2019006283A1 (en) | 2019-01-03 |
| KR102630575B1 (ko) | 2024-01-29 |
| MX2021015656A (es) | 2022-02-03 |
| BR112019027259A2 (pt) | 2020-07-14 |
| JP7690284B2 (ja) | 2025-06-10 |
| SG11201911937UA (en) | 2020-01-30 |
| IL271601A (en) | 2020-02-27 |
| US20220169615A1 (en) | 2022-06-02 |
| JP2020526520A (ja) | 2020-08-31 |
| EP3644993B1 (en) | 2023-08-02 |
| AU2018294314B2 (en) | 2024-09-19 |
| CN111093651B (zh) | 2023-06-06 |
| EP3644993A4 (en) | 2021-03-10 |
| EP3644993A1 (en) | 2020-05-06 |
| MX2019014885A (es) | 2020-02-13 |
| US12421195B2 (en) | 2025-09-23 |
| AU2018294314A1 (en) | 2020-02-06 |
| KR20200020916A (ko) | 2020-02-26 |
| MX391848B (es) | 2025-03-19 |
| US11236049B2 (en) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090119A1 (ru) | Аморфные и кристаллические формы ido-ингибиторов | |
| EA201691135A1 (ru) | Новые ингибиторы глутаминазы | |
| PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
| MX382671B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| EA201891103A1 (ru) | Композиции для лечения спинальной мышечной атрофии | |
| EA201691579A1 (ru) | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b | |
| EA201792259A1 (ru) | Бензимидазольные и имидазопиридиновые карбоксимидамидные соединения | |
| EA201692356A1 (ru) | Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида | |
| EA201792028A1 (ru) | Альфа-цинамидные соединения и композиции как ингибиторы hdac8 | |
| EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
| EA201690598A1 (ru) | Аминогетероарил бензамиды в качестве ингибиторов киназы | |
| EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| EA201890331A1 (ru) | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена | |
| EA201691512A1 (ru) | Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2 | |
| EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA202190960A1 (ru) | Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30) | |
| EA201891379A1 (ru) | Ингибиторы тирозинкиназы брутона и способы их применения | |
| EA201591360A1 (ru) | Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| EA201790818A1 (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1 | |
| EA201791259A1 (ru) | Производные пиперидина в качестве ингибиторов hdac1/2 | |
| EA201992137A1 (ru) | ПИРИМИДОПИРИМИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ Wee-1 | |
| EA201690523A1 (ru) | Триазолопиридины, композиции и способы их применения | |
| EA202091003A1 (ru) | Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3 | |
| EA201791174A1 (ru) | Антимикотическое соединение |